JP2009519226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519226A5 JP2009519226A5 JP2008541446A JP2008541446A JP2009519226A5 JP 2009519226 A5 JP2009519226 A5 JP 2009519226A5 JP 2008541446 A JP2008541446 A JP 2008541446A JP 2008541446 A JP2008541446 A JP 2008541446A JP 2009519226 A5 JP2009519226 A5 JP 2009519226A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- halogens
- alkyl
- optionally substituted
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052736 halogen Inorganic materials 0.000 claims 31
- 150000002367 halogens Chemical class 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000002431 hydrogen Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- BGJGBFZVODHBGF-UHFFFAOYSA-N 3-[[4-[1-[4-(4-tert-butylphenyl)anilino]-3-methylbutyl]benzoyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)C=CC=1C(CC(C)C)NC(C=C1)=CC=C1C1=CC=C(C(C)(C)C)C=C1 BGJGBFZVODHBGF-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- RSTCYOJNAFOPJU-UHFFFAOYSA-N 3-[[4-[3-methyl-1-[4-[4-(trifluoromethyl)phenyl]anilino]butyl]benzoyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)C=CC=1C(CC(C)C)NC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 RSTCYOJNAFOPJU-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- -1 3,3-dimethylbutyl Chemical group 0.000 claims 2
- JLDJSIOVMRCTAX-UHFFFAOYSA-N 3-[[4-[1-[4-(4-cyanophenyl)anilino]-3-methylbutyl]benzoyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)C=CC=1C(CC(C)C)NC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 JLDJSIOVMRCTAX-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- UQPIEHMOLHNOQO-UHFFFAOYSA-N 3-[[4-[1-(3-methoxy-4-phenylanilino)hexyl]benzoyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)C=CC=1C(CCCCC)NC(C=C1OC)=CC=C1C1=CC=CC=C1 UQPIEHMOLHNOQO-UHFFFAOYSA-N 0.000 claims 1
- HDOXXWVGJGIWNK-UHFFFAOYSA-N 3-[[4-[1-[3,5-dimethyl-4-[4-(trifluoromethyl)phenyl]anilino]-3-methylbutyl]benzoyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)C=CC=1C(CC(C)C)NC(C=C1C)=CC(C)=C1C1=CC=C(C(F)(F)F)C=C1 HDOXXWVGJGIWNK-UHFFFAOYSA-N 0.000 claims 1
- LXYGMSILKVAJIL-UHFFFAOYSA-N 3-[[4-[1-[4-(4-cyanophenyl)anilino]hexyl]benzoyl]amino]propanoic acid Chemical compound C=1C=C(C(=O)NCCC(O)=O)C=CC=1C(CCCCC)NC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 LXYGMSILKVAJIL-UHFFFAOYSA-N 0.000 claims 1
- 125000000439 4-methylpentoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73762705P | 2005-11-17 | 2005-11-17 | |
| US60/737,627 | 2005-11-17 | ||
| PCT/US2006/060586 WO2007106181A2 (en) | 2005-11-17 | 2006-11-07 | Glucagon receptor antagonists, preparation and therapeutic uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009519226A JP2009519226A (ja) | 2009-05-14 |
| JP2009519226A5 true JP2009519226A5 (enExample) | 2010-11-25 |
| JP5107253B2 JP5107253B2 (ja) | 2012-12-26 |
Family
ID=38474434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541446A Active JP5107253B2 (ja) | 2005-11-17 | 2006-11-07 | グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7696248B2 (enExample) |
| EP (1) | EP1951661B1 (enExample) |
| JP (1) | JP5107253B2 (enExample) |
| CN (1) | CN101309895B (enExample) |
| AU (1) | AU2006340002B2 (enExample) |
| BR (1) | BRPI0618349A2 (enExample) |
| CA (1) | CA2629348C (enExample) |
| CY (1) | CY1113159T1 (enExample) |
| DK (1) | DK1951661T3 (enExample) |
| ES (1) | ES2391109T3 (enExample) |
| PL (1) | PL1951661T3 (enExample) |
| PT (1) | PT1951661E (enExample) |
| SI (1) | SI1951661T1 (enExample) |
| WO (1) | WO2007106181A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1758853E (pt) * | 2004-06-14 | 2010-03-02 | Lilly Co Eli | Antagonistas do receptor de glucagon, sua preparação e usos terapêuticos |
| MX2009008534A (es) | 2007-02-09 | 2009-11-23 | Metabasis Therapeutics Inc | Antagonistas novedosos del receptor de glucagon. |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR101616140B1 (ko) * | 2008-03-05 | 2016-04-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 복소환 화합물 |
| EP2799428B1 (en) | 2008-08-13 | 2016-11-16 | Metabasis Therapeutics, Inc. | Glucagon antagonists |
| US8361959B2 (en) | 2008-10-03 | 2013-01-29 | Merck Sharp & Dohme Corp. | Spiro-imidazolone derivatives as glucagon receptor antagonists |
| PE20100443A1 (es) * | 2009-02-06 | 2010-06-25 | Takeda Pharmaceutical | Derivados del acido fenil-carbonil-amino-propanoico como antagonistas del glucagon |
| EP2480077B1 (en) | 2009-09-22 | 2015-02-18 | Merck Sharp & Dohme Corp. | Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| AU2011346670B2 (en) * | 2010-12-23 | 2015-05-07 | Pfizer Inc. | Glucagon receptor modulators |
| PH12013501557A1 (en) | 2011-02-08 | 2019-06-03 | Pfizer | Glucagon receptor modulator |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CA2837088A1 (en) * | 2011-05-23 | 2012-11-29 | Janssen Pharmaceutica Nv | Biphenyl derivatives useful as glucagon receptor antagonists |
| EP2714661B1 (en) * | 2011-05-23 | 2015-09-30 | Janssen Pharmaceutica, N.V. | Picolinamido - propanoic acid derivatives useful as glucagon receptor antagonists |
| RU2013157388A (ru) * | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104350040B (zh) * | 2012-03-29 | 2016-06-01 | 武田药品工业株式会社 | 芳环化合物 |
| EP3065736B1 (en) | 2013-11-04 | 2018-11-14 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions thereof, and methods of use |
| WO2015191900A1 (en) | 2014-06-12 | 2015-12-17 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
| JP2016052300A (ja) * | 2014-09-03 | 2016-04-14 | 日立化成株式会社 | 生体物質捕獲システム |
| JP2021513564A (ja) | 2018-02-13 | 2021-05-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体拮抗薬 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420557D0 (en) | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
| AU4537900A (en) * | 1999-05-17 | 2000-12-05 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| AU2002365622A1 (en) | 2001-12-03 | 2003-06-17 | Novo Nordisk A/S | Novel glucagon antagonists |
| US6881746B2 (en) * | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| JP2006500325A (ja) | 2002-06-27 | 2006-01-05 | ノボ ノルディスク アクティーゼルスカブ | 新規なグルカゴンアンタゴニスト |
| WO2004056763A2 (en) | 2002-12-20 | 2004-07-08 | Novo Nordisk A/S | Novel glucagon antagonists |
| US8318760B2 (en) | 2005-03-21 | 2012-11-27 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use |
-
2006
- 2006-11-07 ES ES06850109T patent/ES2391109T3/es active Active
- 2006-11-07 DK DK06850109.7T patent/DK1951661T3/da active
- 2006-11-07 PT PT06850109T patent/PT1951661E/pt unknown
- 2006-11-07 US US12/093,054 patent/US7696248B2/en active Active
- 2006-11-07 JP JP2008541446A patent/JP5107253B2/ja active Active
- 2006-11-07 PL PL06850109T patent/PL1951661T3/pl unknown
- 2006-11-07 CN CN2006800429010A patent/CN101309895B/zh active Active
- 2006-11-07 SI SI200631430T patent/SI1951661T1/sl unknown
- 2006-11-07 EP EP06850109A patent/EP1951661B1/en active Active
- 2006-11-07 BR BRPI0618349-2A patent/BRPI0618349A2/pt not_active IP Right Cessation
- 2006-11-07 WO PCT/US2006/060586 patent/WO2007106181A2/en not_active Ceased
- 2006-11-07 CA CA2629348A patent/CA2629348C/en not_active Expired - Fee Related
- 2006-11-07 AU AU2006340002A patent/AU2006340002B2/en not_active Ceased
-
2012
- 2012-09-28 CY CY20121100902T patent/CY1113159T1/el unknown